|
 |
European Pharmaceutical Contractor
|
We estimate that the total market for CROs grew by over 11% in 2002. This is not the spectacular 20% growth that we saw in the mid-1990s, but nonetheless it is a sign of a very healthy industry. The CRO market breaks down to US$5.56 billion for clinical research related activities (60%) and US$3.79 billion (40%) for preclinical toxicology and analysis - a grand total of US$9.39 billion. To put it another way, this is a market equal to the gross national product of Armenia, three times that of Zambia or more than the total health care expenditure of Finland.
It is still an industry dominated by relatively few large companies as Table 1 shows. Using the figures in Table 1 we calculate that the top 30 companies represent 64% of the total market; of these some 10 were private companies but these represented only 12% of the revenues of this group. Thus the 20 largest public companies account for 56% of the total market for CROs, while the top 10 private companies made up approximately 7.7% of the total.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
